So You Want To Build A 340B Specialty Pharmacy. How Hard Can It Be?

December 30, 2024340B, Covered Entities, Drug Manufacturer Restrictions, Specialty Drugs, Specialty Pharmacy

Fair Warning: If you ever dismissively ask that question (above) of someone who’s led the planning and launch of a 340B hospital’s specialty pharmacy, and did it with no outside support, there’s a good chance you’ll get punched. Yes, it’s that difficult.   POST OUTLINE Why is it so hard to build a 340B specialty … Read More

J&J’s Own Numbers Reveal The Fallacy In Drug Manufacturers’ Objections To 340B

October 25, 2024340B, Covered Entities, Drug Manufacturer Restrictions, PBM, Specialty Drugs, Specialty Pharmacy

POST OUTLINE Introduction: Overview Review of Johnson & Johnson’s drug rebate payments in 2023 J&J’s 2023 profit margin Johnson & Johnson’s real rebate problem 340B and the drug industry as a whole Estimated percentage of drug sales supporting 340B health systems Why the actual number is lower than reported The importance of 340B savings & … Read More

Overcome 340B ESP & Other Manufacturer Restrictions With Software And Human Insight

August 28, 2024340B, 340B ESP, Bedside Prescription Delivery, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Overview, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B scripts Retrieving 340B eligible-script data Establishing communication lines between internal and external 340B teams Why specialized software is essential for successful 340B programs The central problem with most 340B programs’ data Why 340B software … Read More

Using 340B To Optimize Patient Care And ROI Throughout Your Health System

August 7, 2024340B, 340B ESP, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Patient Eligibility, Prescription Discounts, Readmissions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

Far too many 340B hospitals overlook pharmacy’s overall potential in their health systems’ revenue cycles. Below is a graphic overview of ProxsysRx’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to … Read More

Empower Your Health System’s 340B Program With Analytics

July 10, 2024340B, Compliance, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Medication Compliance, Patient Eligibility, TPA / TPAs

The automated approach to optimizing 340B savings & patient care while overcoming manufacturer restrictions NOTE: The purpose of this article is to highlight features and functionality any 340B platform needs to optimize a health system’s 340B savings and revenue. That said, we determined that the easiest way to report those features was to describe the … Read More

Is Your 340B Vendor A Partner Or A Parasite?

May 16, 2024340B, Covered Entities, Patient Eligibility, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

Why 340B vendors charging Percentage Of Revenue is wrong. The United States Congress established the 340B statute in 1992 to help non-profit hospitals fill-in the often-backbreaking revenue gaps inherent to their business models — enabling covered entities to replenish eligible prescriptions at significant savings. Savings which they can then pass-along to their patients, many of … Read More

340B Outlook For 2024: Change. Change. And More Change.

April 19, 2024340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

POST OUTLINE 1) What we’ve learned. What it means for your 340B program. Overview of ProxsysRx 340B Team experience and successes Dealing with frequent, unexpected changes 2) Potential 340B developments for 2024 National legislation prospects State regulatory changes 3) Legislative & court updates Bill introduced into House Of Representatives Supreme Court overturns 340B restriction cuts … Read More

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

April 4, 2024340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More

Best Practices For A 340B Hospital Looking To Build An Onsite Specialty Pharmacy

March 28, 2024340B, Outpatient Tracking, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

ProxsysRx recently gathered three of its corporate executives for an in-depth discussion of how an eligible health system can optimize revenues from its 340B program and its retail pharmacy, to help build and fund an onsite specialty pharmacy. Below is a lightly-edited transcript of that discussion. NOTE: If you’d prefer to watch the complete video … Read More

The Best 340B Program Is More Than Just A 340B Program. Much More.

March 12, 2024340B, Bedside Prescription Delivery, Contract Pharmacy, Drug Manufacturer Restrictions, Meds To Beds, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

Congress established the 340B program in 1992 to help non-profit hospitals fill-in the significant revenue gaps inherent to their business models. What the bill’s supporters did not foresee, and what very few eligible health systems realize — even today — is that 340B can function as the central hub of a multi-point program. One that … Read More